The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis
Abstract
Objective: To analyze the clinical and biologic correlates of autoantibody induction during longer‐term tumor necrosis factor α (TNFα) blockade with either the monoclonal antibody infliximab or the soluble receptor etanercept. Methods: Thirty‐four patients with spondylarthropathy (SpA) and 59 patients with rheumatoid arthritis (RA) were treated with infliximab for 2 years. Additionally, 20 patients with SpA were treated with etanercept for 1 year. Sera were blindly analyzed for antinuclear antibodies (ANAs), anti–double‐stranded DNA (anti‐dsDNA) antibodies, anti–extractable nuclear antigen (anti‐ENA) antibodies, and antihistone, antinucleosome, and anticardiolipin antibodies (aCL). The anti‐dsDNA antibodies were isotyped. Results: High numbers of infliximab‐treated patients with SpA or RA had newly induced ANAs (61.8% and 40.7%, respectively) and anti‐dsDNA antibodies (70.6% and 49.2%, respectively) after 1 year, but no further increase between year 1 and year 2 was observed. In contrast, induction of ANAs and anti‐dsDNA antibodies was observed only occasionally in the etanercept‐treated patients with SpA (10% of patients each). Isotyping revealed almost exclusively IgM or IgM/IgA anti‐dsDNA antibodies, which disappeared upon interruption of treatment. Neither infliximab nor etanercept induced other lupus‐related reactivities such as anti‐ENA antibodies, antihistone antibodies, or antinucleosome antibodies, and no clinically relevant lupus‐like symptoms were observed. Similarly, infliximab but not etanercept selectively increased IgM but not IgG aCL titers. Conclusion: The prominent ANA and anti‐dsDNA autoantibody response is not a pure class effect of TNFα blockers, is largely restricted to short‐term IgM responses, and is not associated with other serologic or clinical signs of lupus. Similar findings with aCL suggest that modulation of humoral immunity may be a more general feature of infliximab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00701-7 · Cited by 327
The use of laboratory tests in the diagnosis of SLE
Egner, W. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.6.424 · Cited by 316
Werle, E., Blazek, M., & Fiehn, W. (1992) · Lupus · doi:10.1177/096120339200100606 · Cited by 39
Warrington (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200101)44:1 · Cited by 2
Cited by
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
de Gannes, G. C., Ghoreishi, M., Pope, J., Russell, A., Bell, D., Adams, S., Shojania, K., Martinka, M., & Dutz, J. P. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.2.223 · Cited by 325
Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
Ghabril, M., Bonkovsky, H. L., Kum, C., Davern, T., Hayashi, P. H., Kleiner, D. E., Serrano, J., Rochon, J., Fontana, R. J., & Bonacini, M. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.025 · Cited by 196
Risk of drug-induced liver injury from tumor necrosis factor antagonists
Björnsson, E. S., Gunnarsson, B. I., Gröndal, G., Jonasson, J. G., Einarsdottir, R., Ludviksson, B. R., Gudbjörnsson, B., & Olafsson, S. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.062 · Cited by 118
Popescu, M., Cabrera-Martinez, B., & Winslow, G. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900484 · Cited by 72
Metadata
- Authors
- de Rycke, L., Baeten, D., Kruithof, E., Van den Bosch, F., Veys, E. M., & de Keyser, F.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-06-28
- Volume
- 52
- Issue
- 7
- Pages
- 2192-2201
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2077358378
- Cited by
- 172
- References
- 6
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis. https://app.cochat.ai/papers/10.1002/art.21190
- The paper
- de Rycke, L., Baeten, D., Kruithof, E., Van den Bosch, F., Veys, E. M., & de Keyser, F. (2005). Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.21190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.